Phase III study of two different dosing schedules of erythropoietin in <font color="blue">anemic_5</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">cancer_5</font> <font color="blue">._5</font> <font color="blue">
<br>
<br>_2</font> PURPOSE To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">cancer_5</font> <font color="blue">-_5</font> <font color="blue">associated_5</font> <font color="blue">anemia_5</font> <font color="blue">._5</font> <font color="blue">
<br>_3</font> PATIENTS AND METHODS <font color="blue">Eligible_3</font> <font color="blue">patients_3</font> <font color="blue">were_2</font> <font color="blue">randomly_2</font> <font color="blue">assigned_2</font> <font color="blue">at_2</font> <font color="blue">enrollment_2</font> to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40 K arm ) or 120,000 U of epoetin alfa ( 120 K arm ) SC every 3 weeks for 18 additional weeks . 
<br> RESULTS <font color="blue">Three_7</font> <font color="blue">hundred_7</font> <font color="blue">sixty_7</font> <font color="blue">-_7</font> <font color="blue">five_7</font> <font color="blue">patients_7</font> <font color="blue">were_4</font> <font color="blue">enrolled_4</font> <font color="blue">._4</font> <font color="blue">One_3</font> <font color="blue">hundred_3</font> <font color="blue">eighty_3</font> <font color="blue">-_3</font> <font color="blue">three_3</font> <font color="blue">patients_3</font> <font color="blue">were_3</font> <font color="blue">assigned_3</font> <font color="blue">to_3</font> <font color="blue">the_3</font> <font color="blue">40_3</font> <font color="blue">K_3</font> <font color="blue">arm_3</font> <font color="blue">,_3</font> <font color="blue">and_3</font> <font color="blue">182_3</font> <font color="blue">were_3</font> <font color="blue">assigned_3</font> <font color="blue">to_3</font> <font color="blue">the_3</font> <font color="blue">120_3</font> <font color="blue">K_3</font> <font color="blue">arm_3</font> <font color="blue">._3</font> There was no difference in the proportion of <font color="blue">patients_1</font> <font color="blue">requiring_1</font> <font color="blue">transfusions_1</font> during the study ( 23% in 40 K arm and 18% in 120 K arm , P = .22 ) or specifically during the maintenance phase ( 13% in 40 K arm v 15% in 120 K arm , P = .58 ) . <font color="blue">Patients_1</font> <font color="blue">randomly_1</font> <font color="blue">assigned_1</font> <font color="blue">to_1</font> <font color="blue">the_1</font> <font color="blue">40_1</font> <font color="blue">K_1</font> <font color="blue">arm_1</font> were more likely to have a > or = 2 or > or = 3 g / dL hemoglobin ( Hb ) increment , were more likely to have a drug dose held because of high Hb , and had higher mean end - of - study Hb levels . Toxicities , including thromboembolism , and overall survival were similar . <font color="blue">Patients_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">40_1</font> <font color="blue">K_1</font> <font color="blue">arm_1</font> had a higher global quality of life ( QOL ) at baseline for unclear reasons , whereas <font color="blue">patients_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">120_1</font> <font color="blue">K_1</font> <font color="blue">arm_1</font> had a greater global QOL improvement during the study , so end - of - study QOL was equivalent . 
<br> CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL . The Hb increment is somewhat greater with continued weekly epoetin alfa . Lack of blinding as a result of different treatment schedules may have confounded results .